Ipamorelin Nutrition for Best Outcomes: What to Eat, When to Inject, and How to Get the Most from Every Dose
HealthRX.com
No diet has been shown to change how ipamorelin works
Key numbers
- 14.3%High blood sugar at discharge in patients given ipamorelin in the one published trial, versus 8.6% on placeboSource: fda.gov, as cited Nov 7, 2026
- 0.67 hoursTime after a 15-minute IV infusion when growth hormone peaked in healthy male volunteersSource: pubmed.ncbi.nlm.nih.gov, as cited Nov 7, 2026
- 25.3 hoursMedian time to first tolerated solid meal on ipamorelin, the main trial endpoint; not significant versus 32.6 hours on placeboSource: pubmed.ncbi.nlm.nih.gov, as cited Nov 7, 2026
- 0.03 mg/kgIntravenous ipamorelin dose given twice daily in the bowel resection trial; a research dose, not a recommended oneSource: pubmed.ncbi.nlm.nih.gov, as cited Nov 7, 2026
At a glance
- Approval status / Not FDA-approved; FDA lists ipamorelin acetate among bulk substances that raise significant safety risks for outsourcing-facility compounding [3][4]
- Human dosing on record / Intravenous only: 0.03 mg/kg twice daily in the ileus trial; single 15-minute infusions in a volunteer study [1][2]
- Growth hormone peak after IV dose / 0.67 hours, then a decline to negligible levels [2]
- Terminal half-life / About 2 hours [2]
- High blood sugar at discharge / 14.3% ipamorelin vs 8.6% placebo [3][1]
- Sport status / Prohibited at all times under WADA section S2.2.4 [5]
Is there a diet that makes ipamorelin work better?
Not on current evidence. Advice to inject on an empty stomach or delay eating has no basis in the published human ipamorelin studies [1][2]. Their reported endpoints were meal tolerance and safety in surgical patients, and growth hormone and drug concentrations in volunteers, so none compared a fasted dose with a fed dose, a high-protein day with a low-protein one, or a supplement with placebo.
Both studies gave the drug intravenously, in surgical patients and in healthy volunteers [1][2].
Questions worth asking
What the human studies measured
Ipamorelin is a five-amino-acid synthetic peptide that releases growth hormone at the ghrelin/growth-hormone-secretagogue receptor, not the GHRH receptor [6]. In one small volunteer study, healthy men given 15-minute intravenous infusions at five dose levels had a terminal half-life of about 2 hours; growth hormone rose in a single episode that peaked at 0.67 hours and fell to negligible concentrations at every dose [2]. FDA's review states that it found no human pharmacokinetic, safety or efficacy data for subcutaneous ipamorelin [3].
The one published phase 2 trial enrolled 117 adults having bowel resection, of whom 114 were analyzed after intravenous ipamorelin 0.03 mg/kg or placebo twice daily from postoperative day 1 to 7 [1]. The trial reported high blood sugar at discharge in 14.3% of patients receiving ipamorelin and 8.6% receiving placebo, low potassium in 12.5% versus 3.4%, and insomnia in 10.7% versus 5.2% [3]. Two ipamorelin-treated patients died of surgical complications; FDA said it is unclear whether the deaths were related to ipamorelin but that they raise safety concerns [3]. Median time to first tolerated solid meal, the main endpoint, was 25.3 hours on ipamorelin versus 32.6 hours on placebo, a difference that was not statistically significant (p=0.15) [1]. FDA's review notes that ipamorelin stimulates the GH and IGF-1 axis and may therefore carry the risks listed on approved growth hormone labels, including glucose intolerance and diabetes, and that it found no data showing it would not [3].
Dose, route and legal status
No FDA-approved dose exists. The intravenous regimens used in research, 0.03 mg/kg twice daily in the ileus trial and single 15-minute infusions of 4.21 to 140.45 nmol/kg in the volunteer study, are not recommended doses [1][2][3].
FDA lists ipamorelin acetate among bulk substances that raise significant safety risks for compounding by outsourcing facilities, citing possible immune reactions from aggregation and impurities, difficulty characterizing its unnatural amino acids, and a published study reporting serious adverse events including death when it was given intravenously to improve gastric motility [4]. WADA prohibits ipamorelin at all times, in and out of competition, as a growth hormone secretagogue [5].
Check what you know
Question 1 of 3
Score: 0 right, 0 of 3 answered
Frequently asked questions
When does growth hormone peak after an ipamorelin dose?
Does ipamorelin raise blood sugar?
Is there a standard ipamorelin dose to plan meals around?
Reader questions
What people actually ask
Short answers drawn from the sources this article cites.
When should I eat after taking Ipamorelin?
No meal timing has been shown to change how ipamorelin works, and the published human studies did not test it. Advice to inject on an empty stomach or to wait before eating has no basis in those studies. All human dosing on record was intravenous, in surgical patients and healthy volunteers, so no fed versus fasted dose was compared.
What should I eat while taking peptides?
On current evidence, no diet has been shown to make ipamorelin work better. The human studies did not compare a high-protein day with a low-protein one or a supplement with placebo, and they gave the drug intravenously. The one published phase 2 trial reported high blood sugar at discharge in 14.3% on ipamorelin versus 8.6% on placebo, but it did not test any food.
References
Show all 6 referencesHide references
- Beck DE, Sweeney WB, McCarter MD, Ipamorelin 201 Study Group. Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. Int J Colorectal Dis. 2014;29(12):1527-34.
- Gobburu JV, Agersø H, Jusko WJ, Ynddal L. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharm Res. 1999;16(9):1412-6.
- U.S. Food and Drug Administration.
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
- World Anti-Doping Agency.
- Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-61.